{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:57:58Z","timestamp":1794225478792,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Standardized measures for evaluating patients\u2019 experiences with nonalcoholic steatohepatitis (NASH) and their perceived changes with treatment in clinical trials have been limited. To meet this need, a patient-reported outcome (PRO) measure, NASH-CHECK, was developed to evaluate symptoms and health-related quality of life for patients with NASH. The objective of this study was to conduct a quantitative evaluation of the psychometric properties of NASH-CHECK.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study used data from a phase\u00a02, randomized controlled trial of adult patients with NASH (NCT02855164). Analyses were conducted to determine the optimal scoring of NASH-CHECK and to evaluate reliability, construct validity, and ability to detect change in NASH-CHECK scale scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data were available for 253 patients with NASH (61% female; mean [standard deviation] age\u2009=\u200953 [12] years). Following initial item-level analyses, including correlations and exploratory factor analysis, three items were removed from the measure. Confirmatory factor analysis supported the formation of four multi-item scales (Cognitive Symptoms, Activity Limitations, Social Impact, and Emotional Impact) and five single-item scales (Abdominal Pain, Abdominal Bloating, Fatigue, Sleep, and Itchy Skin). Psychometric analyses of the final NASH-CHECK scales provided support for their internal reliability, test\u2013retest reliability, construct validity, and ability to detect change.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results support NASH-CHECK as a reliable, valid, and responsive measure to assess patients\u2019 perspectives of symptoms and the health-related quality of life impact of NASH in clinical trials and in routine practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-023-00589-5","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T11:02:25Z","timestamp":1689332545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis"],"prefix":"10.1186","volume":"7","author":[{"given":"James","family":"Twiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Whalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Doward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Magdalena","family":"Balp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford A.","family":"Brass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Cryer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"issue":"1","key":"589_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"589_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2217\/bmm.12.87","volume":"6","author":"M Heeringa","year":"2012","unstructured":"Heeringa M, Hastings A, Yamazaki S et al (2012) Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects? Biomark Med 6(6):743\u2013757. https:\/\/doi.org\/10.2217\/bmm.12.87","journal-title":"Biomark Med"},{"issue":"2","key":"589_CR3","first-page":"74","volume":"11","author":"H Khedmat","year":"2011","unstructured":"Khedmat H, Taheri S (2011) Non-alcoholic steatohepatitis: an update in pathophysiology, diagnosis and therapy. Hepat Mon 11(2):74\u201385","journal-title":"Hepat Mon"},{"issue":"10","key":"589_CR4","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","volume":"17","author":"Y Huber","year":"2019","unstructured":"Huber Y, Boyle M, Hallsworth K et al (2019) Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol 17(10):2085\u20132092. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"589_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1477-7525-8-89","volume":"8","author":"LC Doward","year":"2010","unstructured":"Doward LC, Gnanasakthy A, Baker MG (2010) Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes 8:89. https:\/\/doi.org\/10.1186\/1477-7525-8-89","journal-title":"Health Qual Life Outcomes"},{"key":"589_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.039","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Stepanova M, Taub RA et al (2021) Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2021.07.039","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"589_CR7","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.cgh.2019.02.024","volume":"17","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Stepanova M, Anstee QM et al (2019) Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 17(12):2552\u20132560. https:\/\/doi.org\/10.1016\/j.cgh.2019.02.024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"589_CR8","unstructured":"United States Food and Drug Administration (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed 16 June 2020"},{"key":"589_CR9","unstructured":"United States Food and Drug Administration (2020) Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation. Draft Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders. https:\/\/www.fda.gov\/media\/141565\/download. Accessed 11 Mar 2021"},{"issue":"8","key":"589_CR10","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11136-012-0344-y","volume":"22","author":"BB Reeve","year":"2013","unstructured":"Reeve BB, Wyrwich KW, Wu AW et al (2013) ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res 22(8):1889\u20131905. https:\/\/doi.org\/10.1007\/s11136-012-0344-y","journal-title":"Qual Life Res"},{"key":"589_CR11","unstructured":"European Medicines Agency (2005) Reflection paper on the regulatory guidance for the use of health-related Quality of life (HRQL) measures in the evaluation of medicinal products. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-regulatory-guidance-use-healthrelated-quality-life-hrql-measures-evaluation_en.pdf. Accessed 28 May 2021"},{"issue":"3","key":"589_CR12","doi-asserted-by":"publisher","first-page":"100099","DOI":"10.1016\/j.jhepr.2020.100099","volume":"2","author":"L McSweeney","year":"2020","unstructured":"McSweeney L, Breckons M, Fattakhova G et al (2020) Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. JHEP Rep 2(3):100099. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100099","journal-title":"JHEP Rep"},{"issue":"5","key":"589_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40271-020-00485-w","volume":"14","author":"LC Doward","year":"2021","unstructured":"Doward LC, Balp MM, Twiss J et al (2021) Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study. Patient 14(5):533\u2013543. https:\/\/doi.org\/10.1007\/s40271-020-00485-w","journal-title":"Patient"},{"key":"589_CR14","doi-asserted-by":"publisher","first-page":"106175","DOI":"10.1016\/j.cct.2020.106175","volume":"98","author":"T Hardy","year":"2020","unstructured":"Hardy T, Wonders K, Younes R et al (2020) The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp Clin Trials 98:106175. https:\/\/doi.org\/10.1016\/j.cct.2020.106175","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"589_CR15","first-page":"1461A","volume":"68","author":"AJ Sanyal","year":"2018","unstructured":"Sanyal AJ, Lopez PM, Lawitz E et al (2018) Tropifexor (TXR), an FXR agonist for the treatment of NASH-interim results from first two parts of phase 2b study flight-FXR. Hepatology 68(1):1461A-1462A","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"589_CR16","doi-asserted-by":"publisher","first-page":"101A","DOI":"10.1002\/hep.31578","volume":"72","author":"KJ Lucas","year":"2020","unstructured":"Lucas KJ, Lopez P, Lawitz EJ et al (2020) Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study. Hepatology 72(1 Suppl):101A-102A. https:\/\/doi.org\/10.1002\/hep.31578","journal-title":"Hepatology"},{"issue":"2","key":"589_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","volume":"8","author":"D Wild","year":"2005","unstructured":"Wild D, Grove A, Martin M et al (2005) Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health 8(2):94\u2013104. https:\/\/doi.org\/10.1111\/j.1524-4733.2005.04054.x","journal-title":"Value Health"},{"issue":"2","key":"589_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/gut.45.2.295","volume":"45","author":"ZM Younossi","year":"1999","unstructured":"Younossi ZM, Guyatt G, Kiwi M et al (1999) Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 45(2):295\u2013300. https:\/\/doi.org\/10.1136\/gut.45.2.295","journal-title":"Gut"},{"issue":"10","key":"589_CR19","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"issue":"4","key":"589_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45(4):846\u2013854. https:\/\/doi.org\/10.1002\/hep.21496","journal-title":"Hepatology"},{"issue":"2","key":"589_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","volume":"59","author":"R Lichtinghagen","year":"2013","unstructured":"Lichtinghagen R, Pietsch D, Bantel H et al (2013) The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 59(2):236\u2013242. https:\/\/doi.org\/10.1016\/j.jhep.2013.03.016","journal-title":"J Hepatol"},{"issue":"11","key":"589_CR22","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1515\/CCLM.2010.315","volume":"48","author":"F Ceriotti","year":"2010","unstructured":"Ceriotti F, Henny J, Queralto J et al (2010) Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study. Clin Chem Lab Med 48(11):1593\u20131601. https:\/\/doi.org\/10.1515\/CCLM.2010.315","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"589_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10705519909540118","volume":"6","author":"Hu Lt","year":"1999","unstructured":"Lt Hu, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model 6(1):1\u201355. https:\/\/doi.org\/10.1080\/10705519909540118","journal-title":"Struct Equ Model"},{"key":"589_CR24","unstructured":"Yu C-Y (2002) Evaluating cutoff criteria of model fit indices for latent variable models with binary and continuous outcomes. Doctoral Dissertation. http:\/\/www.statmodel.com\/download\/Yudissertation.pdf. Accessed 3 Oct 2022"},{"key":"589_CR25","volume-title":"Health measurement scales: a practical guide to their development and use","author":"DL Streiner","year":"1995","unstructured":"Streiner DL, Norman GR (1995) Health measurement scales: a practical guide to their development and use, 2nd edn. Oxford University Press, Oxford","edition":"2"},{"key":"589_CR26","volume-title":"Test theory: a unified treatment","author":"RP McDonald","year":"1999","unstructured":"McDonald RP (1999) Test theory: a unified treatment. L. Erlbaum Associates, Mahwah"},{"issue":"1","key":"589_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/01466216010251005","volume":"25","author":"T Raykov","year":"2016","unstructured":"Raykov T (2016) Bias of coefficient afor fixed congeneric measures with correlated errors. Appl Psychol Meas 25(1):69\u201376. https:\/\/doi.org\/10.1177\/01466216010251005","journal-title":"Appl Psychol Meas"},{"issue":"1","key":"589_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989x.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw KO, Wong SP (1996) Forming inferences about some intraclass correlation coefficients. Psychol Methods 1(1):30\u201346. https:\/\/doi.org\/10.1037\/1082-989x.1.1.30","journal-title":"Psychol Methods"},{"key":"589_CR29","volume-title":"Psychometric theory","author":"JC Nunnally","year":"1994","unstructured":"Nunnally JC, Bernstein IH (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York","edition":"3"},{"issue":"1","key":"589_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J (1992) A power primer. Psychol Bull 112(1):155\u2013159. https:\/\/doi.org\/10.1037\/\/0033-2909.112.1.155","journal-title":"Psychol Bull"},{"issue":"7","key":"589_CR31","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"V Ratziu","year":"2005","unstructured":"Ratziu V, Charlotte F, Heurtier A et al (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128(7):1898\u20131906. https:\/\/doi.org\/10.1053\/j.gastro.2005.03.084","journal-title":"Gastroenterology"},{"issue":"4","key":"589_CR32","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/hep.27678","volume":"61","author":"AJ Sanyal","year":"2015","unstructured":"Sanyal AJ, Friedman SL, McCullough AJ et al (2015) Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-US Food and Drug Administration Joint Workshop. Hepatology 61(4):1392\u20131405. https:\/\/doi.org\/10.1002\/hep.27678","journal-title":"Hepatology"},{"issue":"6","key":"589_CR33","first-page":"2943","volume":"7","author":"B Ravinder","year":"2020","unstructured":"Ravinder B, Saraswathi AB (2020) Literature review of cronbachalpha coefficient (\u0391) and Mcdonald\u2019s omega coefficient (\u03a9). Eur J Mol Clin Med 7(6):2943\u20132949","journal-title":"Eur J Mol Clin Med"},{"issue":"1","key":"589_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11336-003-0974-7","volume":"70","author":"RE Zinbarg","year":"2005","unstructured":"Zinbarg RE, Revelle W, Yovel I et al (2005) Cronbach\u2019s \u03b1, Revelle\u2019s \u03b2, and Mcdonald\u2019s \u03c9H: their relations with each other and two alternative conceptualizations of reliability. Psychometrika 70(1):123\u2013133. https:\/\/doi.org\/10.1007\/s11336-003-0974-7","journal-title":"Psychometrika"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00589-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00589-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00589-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T11:03:20Z","timestamp":1689332600000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00589-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00589-5","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The FLIGHT-FXR study was approved by appropriate Institutional Review Boards at each center and all participants provided written consent. The RTI Institutional Review Board (Federalwide Assurance Number 3331) determined the use of anonymized trial data for the purpose of the post hoc psychometric analysis did not require separate Institutional Review Board approval or oversight.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was completed under a research contract between RTI Health Solutions and Novartis Pharma AG and was funded by Novartis Pharma AG. JT, DW, and LD are salaried employees of RTI Health Solutions. MMB is a salaried employee of Novartis. CAB was a salaried employee of Novartis at the time the study was conducted. DC is a salaried employee of the Global Liver Institute, which received consulting fees from Novartis in support of this research. AS has received research grants and consulting fees from Novartis. QMA has received research grants and consulting fees from Novartis and is participating in research collaborations with Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}